Related Experiment Videos
Genetically engineered insulin analogs: diabetes in the new millenium
1Section of Endocrinology, Veterans Affairs Medical Center, Phoenix, Arizona 85012, USA.
Pharmacological Reviews
|March 4, 2000
Summary
New insulin analogs, including rapid- and long-acting types, offer improved glucose control for diabetes management. These advancements promise more individualized treatment strategies and better glycemic outcomes without increasing hypoglycemia.
Area of Science:
- Endocrinology
- Pharmacology
- Biotechnology
Background:
- Tight glucose control is crucial for minimizing diabetic complications.
- Current insulin formulations present pharmacokinetic challenges to achieving sustained normoglycemia.
- Advances in insulin therapy were historically limited to purity and formulation characteristics.
Purpose of the Study:
- To explore the impact of molecular genetic techniques on creating improved insulin analogs.
- To evaluate the therapeutic potential of novel insulin analogs for diabetes management.
- To discuss the future of individualized diabetes treatment strategies using advanced insulin analogs.
Main Methods:
- Review of clinical data on insulin analogs, including Lispro.
- Analysis of pharmacokinetic properties of different insulin preparations.
- Discussion of molecular genetic techniques for insulin analog development.
Main Results:
- The insulin analog Lispro demonstrated improved glycemic control without increased hypoglycemia.
- Short-acting insulin analogs may be better suited with true basal insulin than NPH insulin.
- Future long-acting analogs hold promise for maximizing the benefits of existing short-acting analogs.
Conclusions:
- Insulin analogs represent a significant advancement in diabetes care.
- Novel insulin analogs offer potential for more individualized and effective glycemic control.
- Further development of insulin analogs aims for enhanced stability, reduced variability, and selective action.